Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) EBT: 2010-2025

Historic EBT for Heron Therapeutics (HRTX) over the last 11 years, with Sep 2025 value amounting to -$4.1 million.

  • Heron Therapeutics' EBT rose 8.19% to -$4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 106.16%. This contributed to the annual value of -$14.0 million for FY2024, which is 87.39% up from last year.
  • As of Q3 2025, Heron Therapeutics' EBT stood at -$4.1 million, which was down 150.03% from -$1.6 million recorded in Q2 2025.
  • Heron Therapeutics' 5-year EBT high stood at $4.2 million for Q4 2024, and its period low was -$62.9 million during Q1 2022.
  • For the 3-year period, Heron Therapeutics' EBT averaged around -$11.3 million, with its median value being -$4.8 million (2024).
  • Its EBT has fluctuated over the past 5 years, first dropped by 20.74% in 2022, then soared by 165.74% in 2025.
  • Quarterly analysis of 5 years shows Heron Therapeutics' EBT stood at -$53.5 million in 2021, then surged by 61.98% to -$20.4 million in 2022, then skyrocketed by 49.79% to -$10.2 million in 2023, then spiked by 140.83% to $4.2 million in 2024, then rose by 8.19% to -$4.1 million in 2025.
  • Its EBT stands at -$4.1 million for Q3 2025, versus -$1.6 million for Q2 2025 and $3.2 million for Q1 2025.